Precision 2 - Afatinib : an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation.

Basic trial information

Phase Treatment type Status Age Trial IDs
Phase II Drug, Precision medicine Active 18 years and older Precision 2 - Afatinib, 1200.264
EudraCT: 2016-003411-34

Trial description

Condition Stage of disease Intervention
  • EGFR mutation
  • Her2 mutation
  • Her3 mutation
  • Solid tumor, unspecified, adult
Advanced, Metastatic Drug: Afatinib, BIBW 2992, GILOTRIF (Oral)
Drug: Paclitaxel, Taxol (IV)

Brief study description

The primary objective is to evaluate the objective response rate (CR+PR), using RECIST 1.1 criteria, of afatinib in cancers harbouring either an EGFR mutation, a HER2 mutation or a HER3 mutation, excluding EGFR mutated NSCLC and providing that there is no other tumour-specific genotype-based trial in Belgium for which the patient is eligible.

Trial contact Information

Trial lead sponsors / Collaborators


Participating clinical centers

CHU Liège PI: Collignon Joelle
Contact name: Catot Amandine
GHDC PI: Canon Jean-Luc
Contact name: Canon Jean-Luc
Jessa Ziekenhuis PI: Mebis Jeroen
Contact name: Tullen Ann
UZ Antwerpen PI: Rolfo Christian
Contact name: Van Gerwen Sam
Institut Jules Bordet PI: Aftimos Philippe
Contact name: Bergstrom Annakim
Institut Roi Albert II - Cliniques universitaires Saint-Luc / UCL Bruxelles PI: Machiels Jean-Pascal
Contact name: Papier Matthias
UZ Brussel PI: Decoster Lore
UZ Gent PI: Rottey Sylvie
Contact name: De Letter Rita
Centre Hospitalier de Luxembourg PI: Berchem Guy
Contact name: Graas Jerome